TUCSON, Ariz., June 07, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, the company’s president and chief executive officer, is scheduled to present to investors at the 36th Annual Growth Stock Conference hosted by William Blair & Company, L.L.C. on June 15, 2016 at 8:00 a.m. Central Time at the Four Seasons Hotel in Chicago, Illinois. The presentation will be accessible from the investor portal of the company’s website at http://ir.axdx.com.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. The company’s initial ID/AST platform and test for positive blood culture samples, the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit, utilize proprietary molecular and phenotypic detection technologies which have the potential to significantly decrease the time to result while achieving high sensitivity and specificity. For more information about the company and products visit www.acceleratediagnostics.com.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Certain of the statements made in this press release are forward looking, such as those, among others, regarding our projections as to when certain key business milestones may be achieved, including marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the system and kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Source:Accelerate Diagnostics, Inc.